The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.

Cavit BozSerkan OzakbasMurat TerziRana KarabudakSerhan SevimRecai TurkogluAysun SoysalBelgin Petek BalcıHüsnü EfendiÖmer Faruk TuranNur YüceyarMehmet Fatih YetkinSerap Zengin KarahanMeltem DemirkıranSibel GulerKadriye AganNefati KıylıoğluCavid BabaAsli TuncerMesrure Köseoğlu

Published in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2023)

Natalizumab and ocrelizumab exhibited similar effects on relapse control, and both were associated with better relapse control than fingolimod. The effects of the three therapies on disability outcomes were similar.

Keyphrases

multiple sclerosis
white matter
free survival
type diabetes
glycemic control
disease activity